/
Oncology
Small Cell Lung Cancer
565
Pipeline Programs↗
1.1K
Active Trials↗
335
Companies Involved↗
Small Cell Lung Cancer is a highly competitive landscape with 565 programs across 335 companies. The most active players are Shanghai Henlius Biotech, Sichuan Baili Pharmaceutical Co., Ltd., Merck & Co.. 165 programs are in Phase 3.
Intelligence
Pipeline Metrics
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Competition
Competitive Landscape
Bubble size = clinical trials
Approved
Phase 3
Phase 2
Phase 1
Preclinical
Key Players
Top Companies Companies ranked by the number of pipeline programs they run for this disease.
Pipeline
Programs by Phase
Preclinical125
Phase 174
Phase 2201
Phase 3165
Approved
No programs
Analysis
Modality Breakdown
83%
Small molecule
425 of 511 classified programs — the dominant modality here.
Small molecule leads; the ring shows all 511 classified programs, each share of the total. Modality classified for 95% of 565 pipeline programs.
Analysis
Trial Status
3,776
clinical trials
Completed1,541 · 41%
Recruiting557 · 15%
Terminated512 · 14%
Unknown status448 · 12%
Active, not recruiting309 · 8%
Not yet recruiting233 · 6%
Other176 · 5%
Clinical Trials
Trial Activity
3776 trials
Page 1 of 252
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)